Literature DB >> 22740013

Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010.

Kate Smolina1, F Lucy Wright, Mike Rayner, Michael J Goldacre.   

Abstract

BACKGROUND: There are limited population-based national data on prognosis in survivors of acute myocardial infarction (AMI), particularly on long-term survival and the risk of recurrence. METHODS AND
RESULTS: Record linkage of hospital and mortality data identified 387 452 individuals in England who were admitted to hospital with a main diagnosis of AMI between 2004 and 2010 and who survived for at least 30 days. Seven years after an AMI, the risk of death from any cause in survivors of first or recurrent AMI was, respectively, 2 and 3 times higher than that in the English general population of equivalent age. For all survivors of a first AMI, the risk of a second AMI was highest during the first year and the cumulative risk increased more gradually thereafter. For men, 1- and 7-year cumulative risks were 5.6% (95% confidence interval [CI], 5.5-5.7) and 13.9% (95% CI, 13.7-14.1); for women, they were 7.2% (95% CI, 7.1-7.4) and 16.2% (95% CI, 16.0-16.5). Older age, higher deprivation, no revascularization procedures, and presence of comorbidities were associated with higher recurrence risk.
CONCLUSIONS: Survivors of both first and recurrent AMI remained at a significantly higher risk of death compared with the general population for at least 7 years after the event. For survivors of first AMI, the influence of predisposing factors for second AMI lessened with time after the initial event. The results reinforce the importance of acute clinical care and secondary prevention in improving long-term prognosis of hospitalized AMI patients.

Entities:  

Mesh:

Year:  2012        PMID: 22740013     DOI: 10.1161/CIRCOUTCOMES.111.964700

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  65 in total

1.  A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.

Authors:  Dominic Mitchell; Jason R Guertin; Anick Dubois; Marie-Pierre Dubé; Jean-Claude Tardif; Ange Christelle Iliza; Fiorella Fanton-Aita; Alexis Matteau; Jacques LeLorier
Journal:  Mol Diagn Ther       Date:  2018-04       Impact factor: 4.074

2.  Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.

Authors:  Ankur Pandya; Stephen Sy; Sylvia Cho; Milton C Weinstein; Thomas A Gaziano
Journal:  JAMA       Date:  2015-07-14       Impact factor: 56.272

3.  The changing epidemiology of myocardial infarction in Olmsted County, Minnesota, 1995-2012.

Authors:  Yariv Gerber; Susan A Weston; Ruoxiang Jiang; Véronique L Roger
Journal:  Am J Med       Date:  2014-09-28       Impact factor: 4.965

4.  Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves.

Authors:  Ankur Pandya; Stephen Sy; Sylvia Cho; Sartaj Alam; Milton C Weinstein; Thomas A Gaziano
Journal:  Med Decis Making       Date:  2017-05-10       Impact factor: 2.583

5.  Development and Validation of PREDICT-DM: A New Microsimulation Model to Project and Evaluate Complications and Treatments of Type 2 Diabetes Mellitus.

Authors:  Pooyan Kazemian; Deborah J Wexler; Naomi F Fields; Robert A Parker; Amy Zheng; Rochelle P Walensky
Journal:  Diabetes Technol Ther       Date:  2019-06       Impact factor: 6.118

6.  Sleep Duration and Myocardial Infarction.

Authors:  Iyas Daghlas; Hassan S Dashti; Jacqueline Lane; Krishna G Aragam; Martin K Rutter; Richa Saxena; Céline Vetter
Journal:  J Am Coll Cardiol       Date:  2019-09-10       Impact factor: 24.094

Review 7.  The pharmacodynamic and clinical trial evidence for statin dose.

Authors:  Simon B Dimmitt; Hans G Stampfer; John B Warren
Journal:  Br J Clin Pharmacol       Date:  2018-04-16       Impact factor: 4.335

8.  A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Authors:  Molly Melhem; Tor Jensen; Larissa Reinkensmeyer; Luke Knapp; Jordan Flewellyn; Lawrence Schook
Journal:  J Vis Exp       Date:  2015-06-14       Impact factor: 1.355

9.  Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Abdullah Pandor; Daniel Pollard; Tim Chico; Robert Henderson; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

10.  Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore.

Authors:  Wen Bing Brandon Chua; Hua Heng McVin Cheen; Ming Chai Kong; Li Li Chen; Hwee Lin Wee
Journal:  Int J Clin Pharm       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.